The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory body scheduled to formally discuss BPC-157-related substances on July 23, 2026. Understanding how this committee operates — and what its recommendations actually mean — is essential context for anyone following the BPC-157 regulatory story.
What is an FDA advisory committee?
The FDA uses advisory committees as a formal mechanism to get independent expert input on scientific and regulatory questions. Advisory committees are advisory — they provide recommendations, but the FDA makes the final decision. The agency is not legally required to follow committee recommendations, though it does so in the large majority of cases.
Having advisory committees is a deliberate design choice: it brings outside expertise into regulatory decisions, creates a public forum for evidence review, and provides a degree of independent check on FDA staff conclusions. PCAC meetings are public events — they are typically streamed and materials are posted publicly.
What is the PCAC specifically?
The Pharmacy Compounding Advisory Committee advises the FDA specifically on questions related to the 503A bulks list — the list of drug substances that may be used by traditional compounding pharmacies. The committee reviews:
- Nominations for substances to be added to the 503A bulks list
- Evidence on safety, quality, and clinical need for nominated substances
- FDA staff assessments of each substance under review
Who is on the PCAC?
PCAC members are independent experts appointed by the FDA. The committee typically includes:
- Licensed pharmacists with compounding expertise
- Physicians (often from relevant specialties)
- Pharmacologists or pharmaceutical scientists
- Patient or consumer representatives
- A biostatistician or clinical research expert
Members are vetted for conflicts of interest. Industry employees or others with direct financial interests in the outcome are typically excluded or required to recuse themselves.
How does a PCAC meeting work?
For each substance on the agenda, the typical meeting structure includes:
- FDA staff presentation summarizing available evidence (chemistry, safety, effectiveness, historical use)
- Presentations from nominator(s) if they choose to appear
- Public comments from interested parties (open public hearing)
- Committee deliberation and discussion
- Committee vote on a recommendation
The vote options for 503A nominations typically include: recommend for inclusion, do not recommend for inclusion, and sometimes conditional recommendations or deferrals.
Why the July 2026 PCAC discussion matters
For BPC-157, the PCAC discussion is the first formal, public, evidence-based review by an independent expert body with a vote. Whatever the outcome, the briefing materials released before the meeting will represent the FDA's most comprehensive public assessment of available BPC-157 evidence — including evidence many consumers may not be aware of.
A favorable recommendation moves the process toward rulemaking. An unfavorable one signals where the FDA and the expert community stand on available evidence. Either outcome produces more clarity than currently exists.
After the vote: what happens next?
Following the PCAC recommendation, the FDA reviews the committee's input alongside its own analysis. If the recommendation is favorable, the FDA may initiate a notice of proposed rulemaking — a formal step toward adding BPC-157 to the 503A bulks list. This process still takes significant additional time and does not guarantee a final rule. We will cover each development as it happens.
